EVERSANA – which is pharmaphorum's parent company – said that The AI Agency has been set up in collaboration with Google and ...

Vertex already has FDA approval for NaV1.8 inhibitor Journavx (suzetrigine) in acute pain, with late-stage trials on the go ...

The deal with Arrowhead's Visirna Therapeutics subsidiary – which also includes $265 million in milestones tied to potential ...

The importance of China as a growth market for pharma multinationals is underlined by the news that Sanofi has paid $130 million upfront for Chinese rights to an Arrowhead Pharma drug under review for ...

Hemlibra (emicizumab), the only treatment currently available for haemophilia A via the NHS that doesn't require an ...

From trade associations to medtech innovators and biotech start-ups, here’s a comprehensive look at the latest boardroom ...

The target is to reduce its workforce to less than 5,000 from a level of 5,800 at the end of 2024, said chief executive ...

The results of the SURPASS-CVOT trial showed that dual GLP-1/GIP agonist Mounjaro (tirzepatide) was as effective as Lilly's ...

GSK has become the latest drugmaker to run into difficulties in developing a drug targeting the immune checkpoint receptor ...

MSD has said it will cut $3 billion off its annual costs by the end of 2027 as it prepares for the end of patent protection ...

The recent move to introduce an “Amazon-style” prescription tracking in the NHS App is a crucial first step. People want ...

"For decades, bureaucrats and entrenched interests buried health data and blocked patients from taking control of their ...